Skip to main content
OpenTrials
Completed

NCT Number: NCT07513428

Correlation Analysis Between Peripheral Blood PrPC Levels and Disease Severity and Prognosis in Patients With Acute Cerebral Infarction

The primary objective of this observational study is to investigate alterations in PrPc levels in peripheral blood during acute cerebral infarction, as well as the correlation between these changes and both disease severity and prognosis. Additionally, it aims to explore the association between peripheral blood PrPc and T-cell-mediated inflammatory responses in acute cerebral infarction. Key research questions addressed include: how PrPc concentrations in peripheral blood change during acute cerebral infarction, and whether such variations correlate with clinical severity and patient outcomes. No interventions were administered in this study, and all patients received standard diagnostic and therapeutic care without disruption. Fasting venous blood samples were collected on the morning following hospital admission, and follow-up assessments using the modified Rankin Scale (mRS) were conducted at 90 days post-onset.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Cerebral Infarction

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Hospital of Jilin University

Changchun, Jilin, 130021, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with anterior circulation ischemic stroke who were admitted to the Department of Neurology of the First Hospital of Jilin University within 48 hours of symptom onset and were aged 18-80 years

Exclusion criteria

  • (1) patients who received intravenous thrombolysis or endovascular intervention; (2) patients with infectious diseases, autoimmune diseases, or those receiving immunosuppressive or immunomodulatory therapy; (3) patients with a history of cerebral infarction or intracerebral hemorrhage within the past year; (4) patients with severe hepatic or renal dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding three times the upper limit of normal, serum creatinine levels >265 μmol/L, heart failure, or malignant tumors.

Treatment and study plan

Primary outcomes

  1. 3-month mRS

    Time frame: three months after the onset of the disease

    Functional outcomes were assessed at 3 months by trained medical personnel via telephone interviews using the modified Rankin Scale (mRS). Favorable outcomes were defined as no symptoms to mild disability (mRS 0-2), whereas unfavorable outcomes were defined as moderate disability to death (mRS 3-6).

Sponsors and collaborators

Lead sponsor

The First Hospital of Jilin University

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Apr 7, 2026
Registry last updated
Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.